Microsatellite Instability MSI IHC Test: Comprehensive Cancer Genetic Analysis
Understanding Microsatellite Instability Testing
Microsatellite Instability (MSI) testing represents a cornerstone of modern precision oncology, providing critical insights into tumor biology and treatment response. This advanced immunohistochemistry (IHC) test evaluates the stability of repetitive DNA sequences called microsatellites, which serve as indicators of DNA mismatch repair (MMR) system functionality. When the MMR system fails, microsatellites become unstable, leading to genetic mutations that can drive cancer development and progression.
What Does the MSI IHC Test Measure?
The MSI IHC Test specifically detects the presence or absence of four key DNA mismatch repair proteins:
- MLH1: MutL homolog 1 protein expression
- MSH2: MutS homolog 2 protein expression
- MSH6: MutS homolog 6 protein expression
- PMS2: Postmeiotic segregation increased 2 protein expression
Loss of expression in any of these proteins indicates defective DNA repair mechanisms, which correlates with high microsatellite instability status. This molecular characteristic has profound implications for cancer treatment strategies and patient outcomes.
Who Should Consider MSI IHC Testing?
Clinical Indications and Patient Profiles
This test is particularly important for patients with:
- Newly diagnosed colorectal cancer
- Endometrial cancer cases
- Gastric and gastroesophageal cancers
- Patients with family history of Lynch syndrome
- Individuals with early-onset cancers
- Patients with multiple primary cancers
- Those considering immunotherapy treatment options
Symptoms and Risk Factors
Patients experiencing unexplained weight loss, changes in bowel habits, abnormal bleeding, or those with a strong family history of cancer should discuss MSI testing with their oncologist. Early detection of microsatellite instability can significantly impact treatment decisions and long-term outcomes.
Benefits of MSI IHC Testing
Clinical Advantages and Patient Outcomes
- Immunotherapy Eligibility: MSI-high tumors often respond exceptionally well to immune checkpoint inhibitors
- Hereditary Cancer Screening: Identifies potential Lynch syndrome cases
- Treatment Planning: Guides chemotherapy and targeted therapy decisions
- Prognostic Information: Provides insights into disease progression and recurrence risk
- Family Risk Assessment: Helps identify at-risk family members for preventive screening
Understanding Your Test Results
Interpretation and Clinical Implications
Your MSI IHC test results will fall into one of several categories:
MSI-High (MSI-H)
Indicates significant microsatellite instability with loss of MMR protein expression. This result suggests:
- Potential eligibility for immunotherapy treatments
- Possible Lynch syndrome diagnosis
- Generally better prognosis in certain cancer types
- Increased sensitivity to specific chemotherapy agents
MSI-Stable (MSS)
Normal MMR protein expression patterns indicate stable microsatellite status. This suggests:
- Standard treatment approaches may be appropriate
- Lower likelihood of hereditary cancer syndrome
- Different response patterns to certain therapies
Indeterminate Results
In some cases, additional testing may be recommended for clarification, including molecular MSI testing or genetic counseling.
Test Pricing and Availability
| Test Name | Regular Price | Discount Price |
|---|---|---|
| Microsatellite Instability MSI IHC Test | $626 USD | $400 USD |
Test Specifications
- Turnaround Time: 10 days
- Sample Type: FFPE Tissue Block
- Methodology: Immunohistochemistry (IHC)
- Specialty: Oncology
Nationwide Accessibility
GGC DNA maintains comprehensive testing facilities across the United States, ensuring convenient access to advanced genetic testing services. Our network includes specialized centers in:
- New York City and surrounding metropolitan areas
- Los Angeles and Southern California regions
- Chicago and Midwest locations
- Houston and Texas medical centers
- Phoenix and Southwest facilities
- All major urban centers nationwide
Take Control of Your Cancer Care
The Microsatellite Instability MSI IHC Test provides essential information that can transform your cancer treatment journey. By understanding your tumor’s genetic characteristics, you and your healthcare team can make informed decisions about the most effective treatment strategies.
Ready to schedule your test? Contact our dedicated oncology specialists today to discuss your testing needs and schedule your appointment. Call or WhatsApp us at +1(267) 388-9828 to book your Microsatellite Instability MSI IHC Test and take the next step toward personalized cancer care.
Our experienced genetic counselors and oncology specialists are available to answer your questions and guide you through the testing process. Don’t wait to get the critical information you need for optimal cancer management.
